1112 related articles for article (PubMed ID: 15228497)
21. The potential of parathyroid hormone as a therapy for osteoporosis.
Rubin MR; Bilezikian JP
Int J Fertil Womens Med; 2002; 47(3):103-15. PubMed ID: 12081255
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
23. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.
Zanchetta JR; Bogado CE; Ferretti JL; Wang O; Wilson MG; Sato M; Gaich GA; Dalsky GP; Myers SL
J Bone Miner Res; 2003 Mar; 18(3):539-43. PubMed ID: 12619939
[TBL] [Abstract][Full Text] [Related]
24. Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.
Migliore A; Broccoli S; Massafra U; Bizzi E; Frediani B
Curr Med Res Opin; 2012 Mar; 28(3):467-73. PubMed ID: 22256908
[TBL] [Abstract][Full Text] [Related]
25. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
26. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
27. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
[TBL] [Abstract][Full Text] [Related]
28. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
[TBL] [Abstract][Full Text] [Related]
29. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
30. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
31. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
32. [Effects of parathyroid hormone (teriparatide) on bone mass and quality in osteoporosis].
Marumo K; Saito M
Nihon Rinsho; 2011 Jul; 69(7):1264-9. PubMed ID: 21774369
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy of teriparatide in treatment of glucocorticoid-induced osteoporosis].
Soen S
Clin Calcium; 2012 Mar; 22(3):315-20. PubMed ID: 22370297
[TBL] [Abstract][Full Text] [Related]
34. [Strontium ranelate: a novel concept for the treatment of osteoporosis].
Dimai HP
Wien Klin Wochenschr; 2005 Nov; 117(21-22):728-38. PubMed ID: 16416353
[TBL] [Abstract][Full Text] [Related]
35. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
Dobnig H
Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
[TBL] [Abstract][Full Text] [Related]
37. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
38. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
Lems WF; Hamdy NA; Netelenbos JC
Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
[TBL] [Abstract][Full Text] [Related]
39. Parathyroid hormone as an anabolic therapy for women and men.
Bilezikian JP; Rubin MR; Finkelstein JS
J Endocrinol Invest; 2005; 28(8 Suppl):41-9. PubMed ID: 16329201
[TBL] [Abstract][Full Text] [Related]
40. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
Losada BR; Zanchetta JR; Zerbini C; Molina JF; De la Peña P; Liu CC; Smith RB; Nino AJ; Krohn K; Warner MR
J Clin Densitom; 2009; 12(1):63-70. PubMed ID: 19028124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
